Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9HAD4
UPID:
WDR41_HUMAN
Alternative names:
-
Alternative UPACC:
Q9HAD4; B4DT55; Q7Z792; Q8IWG3; Q8IXA9; Q8NDA7; Q9NV62
Background:
WD repeat-containing protein 41 (WDR41) plays a crucial role as a non-catalytic component of the C9orf72-SMCR8 complex, which is instrumental in regulating autophagy through its guanine nucleotide exchange factor (GEF) activity. This complex facilitates the conversion of GDP-bound RAB8A and RAB39B into their active GTP-bound forms, promoting autophagosome maturation. Additionally, it acts as a negative regulator of autophagy initiation by interacting with and inhibiting the ULK1/ATG1 kinase complex.
Therapeutic significance:
Understanding the role of WD repeat-containing protein 41 could open doors to potential therapeutic strategies.